HI-Bio clinical trials
Acquired by Biogen, Jul 2, 2024 · source ↗
The registry lists 5 studies whose lead sponsor is HI-Bio. 0 are recruiting or about to start. Per ClinicalTrials.gov, last updated Jul 17, 2026.
Before and after it joined Biogen
- First submitted before HI-Bio became part of Biogen
- 5
- First submitted after HI-Bio became part of Biogen
- 0
- Unclear, or no submission date
- 0
By the date each study was first submitted to the registry. The registry lists today's sponsor name and keeps no history, so this says when a study was filed, not who filed it.
Status
- Completed
- 5
Registry sponsor names on this page
- HI-Bio, A Biogen Company5 studies
Something wrong with this grouping? Tell us on the Biogen page.
Studies
Recruiting first, then most recently updated. Showing 5 of 5. All Biogen studies →
- A Study to Learn More About the Safety and Effects of Felzartamab in Adults With Lupus Nephritis Aged 18 to 75 Years OldCompletedNCT06064929Phase 1
Sponsor listed in the registry: HI-Bio, A Biogen Company · First submitted before HI-Bio became part of Biogen
- Clinical Trial to Assess Efficacy and Safety of the Human Anti-CD38 Antibody Felzartamab (MOR202) in IgA NephropathyCompletedNCT05065970Phase 2
Sponsor listed in the registry: HI-Bio, A Biogen Company · First submitted before HI-Bio became part of Biogen
- Trial to Assess Safety and Efficacy of MOR202 in Anti-PLA2R + Membranous Nephropathy (aMN)CompletedNCT04145440Phase 1/2
Sponsor listed in the registry: HI-Bio, A Biogen Company · First submitted before HI-Bio became part of Biogen
- Efficacy, Safety and PK/PD of MOR202 in Anti-PLA2R+ Membranous Nephropathy (aMN) (NewPLACE)CompletedNCT04733040Phase 2
Sponsor listed in the registry: HI-Bio, A Biogen Company · First submitted before HI-Bio became part of Biogen
- A Study of Safety and Drug Levels of HIB210 in Healthy VolunteersCompletedNCT05928585Phase 1
Sponsor listed in the registry: HI-Bio, A Biogen Company · First submitted before HI-Bio became part of Biogen